GM1b is a new member of antigen for serum antibody in Guillain-Barré syndrome.
Serum antibody from some patients with Guillain-Barré syndrome recognized an antigen of a minor component in human brain monosialoganglioside fraction. We purified that antigen, which migrated at a position slightly lower than that of GM1 on a thin-layer chromatogram (TLC), by using Iatrobeads column chromatography and preparative TLC. Structural analyses, including fast atom bombardment mass spectrometry, showed it to be GM1b. An enzyme-linked immunosorbent assay (ELISA) using purified GM1b showed that anti-GM1b antibody was present in 22 of 104 cases tested. No anti-GM1b antibody was present in the sera from control patients with other diseases or from the normal controls. Four sera recognized only GM1b among the 11 ganglioside antigens tested. The other 18 sera had antibodies to other antigens, most of which shared no terminal epitope with GM1b. Eight of nine sera samples with anti-GalNAc-GD1a antibody also had anti-GM1b antibody. Antibody to a minor monosialoganglioside, GM1b, was found to be a useful diagnostic marker for Guillain-Barré syndrome. Further study is needed to determine whether this antibody plays a role in the pathogenetic mechanism of the syndrome.
Kusunoki
S
S
Department of Neurology, Faculty of Medicine, University of Tokyo, Japan.
Iwamori
M
M
Chiba
A
A
Hitoshi
S
S
Arita
M
M
Kanazawa
I
I
D002240:Carbohydrate Sequence; D002855:Chromatography, Thin Layer; D004797:Enzyme-Linked Immunosorbent Assay; D005677:G(M1) Ganglioside / Q000097:blood*; D006801:Humans; D008969:Molecular Sequence Data; D011129:Polyradiculoneuropathy / Q000097:blood*
D005677:G(M1) Ganglioside